Download PDF
Psychiatr Prax 2007; 34(4): 165-174
DOI: 10.1055/s-2006-940058
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Augmentationsstrategien bei Therapieresistenz auf Antidepressiva

Augmentation Strategies for Therapy Resistant Depression - A ReviewMax  Schmauß1 , Thomas  Messer1
  • 1Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Bezirkskrankenhaus Augsburg
Further Information

Publication History

Publication Date:
07 December 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Anliegen Die folgende Arbeit fasst Nutzen und Risiko der bisher bekannten Augmentationstherapien bei therapieresistenten Depressionen zusammen. Methode Die Literaturauswahl erfolgte mittels einer Medline-Datenbankrecherche der Jahrgänge 1990 - 2004. Ergebnisse Unter den Augmentationsstrategien ist die Wirksamkeit der Lithium- und - mit Einschränkungen - auch der T3-Augmentation am besten dokumentiert. Augmentationsstrategien mit atypischen Antipsychotika, Buspiron, Modafinil und dopaminergen Substanzen sind überlegenswerte, jedoch eher nachgeordnete Behandlungsalternativen. Schlussfolgerung Die detaillierte Kenntnis der dargestellten Augmentationsstrategien ermöglicht bessere Behandlungsergebnisse bei therapieresistenten Depressionen.

Abstract

Objective Various pharmacological strategies have been developed to treat such refractory depression, of which augmentation therapies are one of the most important. This article reviews both benefits and risks of all known augmentation therapies. Methods The relevant literature was identified by means of a computerized MEDLINE research on the years 1990 - 2004 and scanning of review articles. Results The efficacy of lithium augmentation is very well documented by a large number of controlled studies - lithium augmentation can therefore be recommended in depression refractory to antidepressant treatment. T3 augmentation is - in contrast to lithium augmentation - only a second-line strategy. There is an increasing number of augmentation therapies with atypical antipsychotics - its efficacy already supported by some well designed placebo controlled studies. Augmentation strategies with buspirone, modafinil and dopaminergic agents show good results in some case series and open studies, but there is a lack of doubleblind placebo controlled studies till now. Other augmentation therapies with stimulants, reserpine, pindolol, SAME and Yohimbine are very interesting clinical research strategies with rather little impact on clinical practice at the moment. Conclusions The distinct knowledge of available augmentation strategies may help to increase response - as well as remission rates in therapy resistant depression.

Schlüsselwörter

Therapieresistente Depression - Augmentationsstrategien - Antidepressiva-Nonresponse

Key words

therapy resistant depression - refractory depression - augmentation strategies

Literatur

  • 1 Amsterdam J D, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression.  Psychiatr Clin North Am. 1996;  19 371-386
    CrossrefPubMedGoogle Scholar
  • 2 Fawcett J. Progress in treatment-resistant and treatment-refractory depression: we still have a long way to go.  J Clin Psychiatry. 1994;  24 214-216
    PubMedGoogle Scholar
  • 3 Nierenberg A A, Amsterdam J D. Treatment-resistant depression: definition and treatment approaches.  J Clin Psychiatry. 1990;  51 (Suppl 6) 39-47
    PubMedGoogle Scholar
  • 4 Guscott R, Grof P. The clinical meaning of refractory depression: a review for the clinician.  Am J Psychiatry. 1991;  148 695-704
    PubMedGoogle Scholar
  • 5 Laux G. Chronifizierte Depressionen. Stuttgart; Enke 1986
    Google Scholar
  • 6 Schmauß M, Meller I. Die „therapieresistente” Depression - Ursachen und Behandlungsmöglichkeiten.  Psychiat Prax. 1989;  16 101-108
    PubMedGoogle Scholar
  • 7 Kielholz P, Terzani S, Gastpar M. Behandlung der therapieresistenten Depressionen.  Dtsch Med Wochenschr. 1978;  103 241-243
    PubMedGoogle Scholar
  • 8 Pöldinger W, Alac S, Krebs-Roubicek E. Zur Behandlung therapierefraktärer Depressionen. In: Kielholz P, Adams C Antidepressive Infusionstherapie. Stuttgart; Thieme 1982
    Google Scholar
  • 9 Möller H J. Therapieresistenz auf Antidepressiva: Risikofaktoren und Behandlungsmöglichkeiten.  Nervenarzt. 1991;  62 658-669
    PubMedGoogle Scholar
  • 10 Stern S L, Mendels J. Drug combinations in the treatment of refractory depression: a review.  J Clin Psychiatry. 1981;  42 368-373
    PubMedGoogle Scholar
  • 11 Nolen W A, Haffmans J. Treatment of resistant depression. Review on the efficacy of various biological treatments, specifically in major depression resistant to cyclic antidepressants.  Intern Clin Psychopharmacol. 1989;  4 217-228
    PubMedGoogle Scholar
  • 12 Helmchen H. Gestuftes Vorgehen bei Resistenz gegen Antidepressiva-Therapie. In: Möller HJ Therapieresistenz unter Antidepressivabehandlung. Berlin, Heidelberg, New York; Springer 1990: 237-250
    Google Scholar
  • 13 Nierenberg A A, White K. What next? A review of pharmacologic strategies for treatment resistant depression.  Psychopharmacol Bull. 1990;  26 429-460
    PubMedGoogle Scholar
  • 14 Möller H J. Non-response to antidepressants: risk factors and therapeutic possibilities.  Clin Psychopharmacol. 1994;  9 (Suppl 2) 17-23
    PubMedGoogle Scholar
  • 15 Möller H J. Therapieresistenz auf Antidepressiva.  Nervenarzt. 2004;  75 499-517
    CrossrefPubMedGoogle Scholar
  • 16 Möller H J. Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression.  Psychopharmakotherapie. 2004;  11 34-41
    PubMedGoogle Scholar
  • 17 Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation.  World J Biol Psychiatry. 2001;  2 57-67
    PubMedGoogle Scholar
  • 18 Joffe R T, Sokolov S T. Thyroid hormones, the brain, and affective disorders.  Crit Rev Neurobiol. 1994;  8 45-63
    PubMedGoogle Scholar
  • 19 Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. TeiI I.  Nervenarzt. 1993;  64 1-10
    PubMedGoogle Scholar
  • 20 Wilson I C, Prange A J, McClane T K. et al . Thyroid-hormone enhancement of imipramine in nonretarded depressions.  N Eng J Med. 1970;  282 1063-1067
    PubMedGoogle Scholar
  • 21 Coppen A, Whybrow P C, Noguera R. et al . The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine.  Arch Gen Psychiatry. 1972;  26 234-241
    PubMedGoogle Scholar
  • 22 Earle B V. Thyroid hormone and tricyclic antidepressants in resistant depressions.  Am J Psychiatry. 1970;  126 1667-1669
    PubMedGoogle Scholar
  • 23 Schwarcz G, Halaris A, Baxter D. et al . Normal thyroid function in desipramine nonresponders converted to responders by the addition of L-triiothyronine.  Am J Psychiatry. 1984;  141 1614-1616
    PubMedGoogle Scholar
  • 24 Targum S D, Greenberg R D, Harmon R L. et al . Thyroid hormone and the TRH stimulation test in refractory depression.  J Clin Psychiatry. 1984;  45 345-346
    PubMedGoogle Scholar
  • 25 Ogura C, Okuma T, Uchida Y, Imai S. Combined thyroid (triiodothyronine)- tricyclic antidepressant treatment in depressive states.  Folia Psychiatr Neurol Jpn. 1974;  28 179-186
    PubMedGoogle Scholar
  • 26 Banki C M. Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women.  Eur J Clin Pharmacol. 1977;  11 311-315
    CrossrefPubMedGoogle Scholar
  • 27 Tsutsui S, Yamazaki Y, Namba T, Tsushima M. Combined therapy of T3 and antidepressants in depression.  J Int Med Res. 1979;  7 138-146
    PubMedGoogle Scholar
  • 28 Extein J. Case reports of l-triiodothyronine potentiation.  Am J Psychiatry. 1982;  139 966-967
    PubMedGoogle Scholar
  • 29 Joffe R T. Triiodothyronine potentiation of the antidepressant effect of phenelzine.  J Clin Psychiatry. 1988;  49 409-410
    PubMedGoogle Scholar
  • 30 Goodwin F K, Prange A J, Post R M. et al . A potentiation of antidepressant effect by l-triiotdothyronine in tricyclic nonresponders.  Am J Psychiatry. 1982;  139 34-38
    PubMedGoogle Scholar
  • 31 Joffe R T, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.  Psychiatry Res. 1990;  32 241-251
    CrossrefPubMedGoogle Scholar
  • 32 Garbutt J C, Mayo J P, Gillette G M. et al . Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation.  Am J Psychiatry. 1986;  143 1038-1039
    PubMedGoogle Scholar
  • 33 Thase M E, Kupfer D J, Jarrett D B. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.  J Clin Psychiatry. 1989;  50 385-388
    PubMedGoogle Scholar
  • 34 Feighner J P, King L J, Schuckit M A. et al . Hormonal potentiation of imipramine and ECT in primary depression.  Am J Psychiatry. 1972;  128 1230-1238
    PubMedGoogle Scholar
  • 35 Birkenhäger T K, Vegt M, Nolen W A. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.  Pharmacopsychiatry. 1997;  30 23-26
    PubMedGoogle Scholar
  • 36 Kirkegaard C, Bjorum N, Cohn D, Lauridsen U B. Thyrotropin-releasing hormone (TRH) stimulation test in manic depressive illness.  Arch Gen Psychiatry. 1978;  35 1017-1021
    PubMedGoogle Scholar
  • 37 Gitlin M J, Weiner H, Fairbanks L. et al . Failure of T3 to potentiate tricyclic antidepressant response.  J Affective Disord. 1987;  13 267-272
    CrossrefPubMedGoogle Scholar
  • 38 Stern R A, Nevels C T, Shelhorse M E. et al . Antidepressant and memory effects of combined thyroid hormone treatment and electroconvulsive therapy: preliminary findings.  Biol Psychiatry. 1991;  30 623-627
    CrossrefPubMedGoogle Scholar
  • 39 Joffe R T, Singer W, Levitt A J, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.  Arch Gen Psychiatry. 1993;  50 387-393
    CrossrefPubMedGoogle Scholar
  • 40 Joffe R T, Lewitt A J, Bagby R M. et al . Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic nonresponders.  Br J Psychiatry. 1993;  163 574-578
    PubMedGoogle Scholar
  • 41 Aronson R, Offman H J, Joffe R T. et al . Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.  Arch Gen Psychiatry. 1996;  53 842-848
    CrossrefPubMedGoogle Scholar
  • 42 Bauer M, Hellweg R, Gräf K J, Baumgartner A. Treatment of refractory depression with high-dose thyroxine.  Neuropsychopharmacology. 1998;  18 444-445
    CrossrefPubMedGoogle Scholar
  • 43 Stein D, Avni J. Thyroid hormones in the treatment of affective disorders.  Acta Psychiatr Scand. 1988;  77 623-636
    PubMedGoogle Scholar
  • 44 Joffe R T, Roy-Byrne P P, Uhde T W, Post R M. Thyroid function and affective illness: A reappraisal.  Biol Psychiatry. 1984;  19 1685-1691
    PubMedGoogle Scholar
  • 45 Prange jr A J, Wilson I C, Breese G R, Lipton M A. Hormonal alteration of imipramine response: a review. In: Sachar EJ Hormones, behavior, and psychopathology. New York; Raven 1976
    Google Scholar
  • 46 Whybrow P C, Prange jr A J. A hypothesis of thyroid-catecholamine receptor interaction.  Arch Gen Psychiatry. 1981;  38 106-113
    PubMedGoogle Scholar
  • 47 Wheatley D. Potentiation of amitriptyline by thyroid hormone.  Arch Gen Psychiatry. 1972;  26 229-233
    PubMedGoogle Scholar
  • 48 Burckhardt C, Raeder E, Müller V. et al . Cardiovascular effects of tricyclic and tetracyclic antidepressants.  J Am Med Assoc. 1978;  239 213-216
    CrossrefPubMedGoogle Scholar
  • 49 Hoffman L, Lowery R. The electrocardiogram in thyrotoxicosis.  Am J Cardiology. 1960;  6 893-904
    CrossrefPubMedGoogle Scholar
  • 50 Breese G R, Taylor T D, Prange jr A J. The effects of triiodothyronine on the disposition and actions of imipramine.  Psychopharmacologia. 1972;  25 101-111
    PubMedGoogle Scholar
  • 51 Worral E P, Moody J P, Peet M. et al . Controlled studies of the acute antidepressant effects of lithium.  Br J Psychiatry. 1979;  135 255-262
    PubMedGoogle Scholar
  • 52 Johnson G F. Lithium in depression: a review of the antidepressant and prophylactic effects of lithium.  Aust NZJ Psychiat. 1987;  21 356-365
    PubMedGoogle Scholar
  • 53 Montigny C de, Grunberg F, Mayer A, Deschenes J P. Lithium induces rapid relief of depression in tricyclic-antidepressant drug non-responders.  Br J Psychiatry. 1981;  138 252-256
    PubMedGoogle Scholar
  • 54 Price L H. Lithium augmentation in tricyclic resistant depression. In: Extein I Treatment of Tricyclic Resistant Depression. Washington DC; American Psychiatric Press 1988
    Google Scholar
  • 55 Schöpf J. Lithiumzugabe zu Thymoleptika als Behandlung therapieresistenter Depressionen.  Nervenarzt. 1989;  60 200-205
    PubMedGoogle Scholar
  • 56 Schou M. Lithium and treatment resistant depression: A review.  Lithium. 1990;  1 3-8
    PubMedGoogle Scholar
  • 57 Austin M PV, Souza F GM, Goodwin G M. Lithium augmentation in antidepressant-resistant patients. A quantitative analysis.  Br J Psychiatry. 1991;  159 510-514
    PubMedGoogle Scholar
  • 58 Montigny C de. Lithium addition in treatment resistant depression.  Intern Clin Psychopharmacol. 1994;  9, Suppl 2 31-35
    PubMedGoogle Scholar
  • 59 Montigny C de, Cournoyer C, Morissette R. et al . Lithium carbonate in tricyclic antidepressant-resistant unipolar depression.  Arch Gen Psychiatry. 1983;  40 1327-1334
    PubMedGoogle Scholar
  • 60 Price L H, Charney D S, Heninger G R. Variability of response to lithium augmentation in refractory depression.  Am J Psychiatry. 1986;  143 1387-1392
    PubMedGoogle Scholar
  • 61 Thase M E, Kupfer D J, Frank E, Jarret D B. Treatment of imipramine resistant recurrent depression II. An open clinical trial of lithium augmentation.  J Clin Psychiatry. 1989;  50 413-417
    PubMedGoogle Scholar
  • 62 Zimmer B, Rosen J, Thornton J E. et al . Adjunctive lithium carbonate in nortriptyline resistant elderly depressed patients.  J Clin Psychopharmacol. 1991;  11 254-256
    PubMedGoogle Scholar
  • 63 Flint A J, Rifat S L. A prospective study of lithium augmentation in antidepressant resistant geriatric depression.  J Clin Psychopharmacol. 1994;  14 353-356
    PubMedGoogle Scholar
  • 64 Bauer M, Döpfmer S. Lithium augmentation in treatment-resistant depression - A meta-analysis of placebo-controlled studies.  J Clin Psychopharmacol. 1999;  19 427-434
    CrossrefPubMedGoogle Scholar
  • 65 Kantor D, McNevin S, Leichner P. et al . The benefit of lithium carbonate adjunct in refractory depression - fact or fiction?.  Can J Psychiatry. 1986;  3 416-418
    PubMedGoogle Scholar
  • 66 Zusky P M, Biederman J, Rosenbaum J F. et al . Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.  J Clin Psychopharmacol. 1988;  8 120-124
    PubMedGoogle Scholar
  • 67 Stein G, Bernadt M. Lithium augmentation therapy in tricyclic resistant depression. A controlled trial using lithium in low and normal doses.  Br J Psychiatry. 1993;  162 634-640
    PubMedGoogle Scholar
  • 68 Heninger G R, Charney D S, Sternberg D E. Lithium carbonate augmentation of antidepressant treatments.  Arch Gen Psychiatry. 1983;  40 1335-1342
    PubMedGoogle Scholar
  • 69 Cournoyer G, Montigny C de, Quellette J. et al .Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Florence, Italy; Abstracts CINP 1984, 19 - 23: 179
    Google Scholar
  • 70 Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study.  Pharmacopsychiatry. 1989;  22 183-187
    PubMedGoogle Scholar
  • 71 Katona C LE, Abou-Saleh M T, Harrison D A. et al . Placebo controlled trial of lithium augmentation of fluoxetine and lofepramine.  Br J Psychiatry. 1995;  166 80-86
    CrossrefPubMedGoogle Scholar
  • 72 Fava M, Rosenbaum J F, Mc Grath P J. et al . Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double blind controlled study.  Am J Psychiatry. 1994;  151 1372-1374
    PubMedGoogle Scholar
  • 73 Baumann P, Nil R, Souche A. et al . A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.  J Clin Psychopharmacol. 1996;  16 307-314
    CrossrefPubMedGoogle Scholar
  • 74 Dinan T G, Barry S. A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders.  Acta Psychiatr Scand. 1989;  80 97-100
    CrossrefPubMedGoogle Scholar
  • 75 Price L H, Conwell Y, Nelson J C. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression.  Am J Psychiatry. 1983;  140 318-322
    PubMedGoogle Scholar
  • 76 Weaver K EC. Lithium for delusional depression.  Am J Psychiatry. 1983;  140 962-963
    PubMedGoogle Scholar
  • 77 Pai M, White A C, Deance A G. Lithium augmentation in the treatment of delusional depression.  Br J Psychiatry. 1986;  148 736-738
    PubMedGoogle Scholar
  • 78 Nelson J C, Mazure C M. Lithium augmentation in psychotic depression refractory to combined drug treatment.  Am J Psychiatry. 1986;  143 363-366
    PubMedGoogle Scholar
  • 79 Joffe R T. T3 and lithium potentiation of tricyclic antidepressants.  Am J Psychiat. 1988;  145 1317-1318
    PubMedGoogle Scholar
  • 80 Garbutt J C, Malekpour M, Brunswick D. et al . Effects of triiodothyronine on drug levels and cardiac function in depressed patients treated with imipramine.  Am J Psychiatry. 1979;  136 980-982
    PubMedGoogle Scholar
  • 81 Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine.  Acta Psychiatr Scand. 1991;  83 188-192
    CrossrefPubMedGoogle Scholar
  • 82 Lingjaerde O, Edlund A H, Gormsen C A. et al . The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression.  Acta Psychiatr Scand. 1974;  50 233-242
    PubMedGoogle Scholar
  • 83 Price L H, Charney D S, Heninger G R. Efficacy of lithium-tranylcypromine treatment in refractory depression.  Am J Psychiat. 1985;  142 619-623
    PubMedGoogle Scholar
  • 84 Madakasira S. Low dose potency of lithium in antidepressant augmentation.  Psychiatr J Univ Ottawa. 1986;  11 107-109
    PubMedGoogle Scholar
  • 85 Dinan T G. Lithium augmentation in sertraline resistant depression: A preliminary dose-response study.  Acta Psychiat Scand. 1993;  88 300-301
    PubMedGoogle Scholar
  • 86 Montigny C de, Elie R, Caillé G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study.  Am J Psychiatry. 1985;  142 220-223
    PubMedGoogle Scholar
  • 87 Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors.  Pharmacopsychiatry. 2001;  34 119-127
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Cowen P J, Mc Cance S L, Ware C J. et al . Lithium in tricyclic resistant depression correlation of increased brain 5 HT function with clinical outcome.  Br J Psychiatry. 1991;  159 341-346
    PubMedGoogle Scholar
  • 89 Nelson J C, Bowers jr M B. Delusional unipolar depression.  Arch Gen Psychiatry. 1978;  35 1321-1328
    PubMedGoogle Scholar
  • 90 Kaskey G B, Nasr S, Meltzer H Y. Drug treatment in delusional depression.  Psychiat Res. 1980;  1 267-277
    PubMedGoogle Scholar
  • 91 Rothschild A J, Samson J A, Bessette M P. et al . Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.  J Clin Psychiatry. 1994;  54 338-342
    PubMedGoogle Scholar
  • 92 Matthews J D, Bottonari K, Polania L M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.  J Clin Psychiatry. 2002;  63 1164-1170
    PubMedGoogle Scholar
  • 93 Rothschild A J, Douglas J W, Tohen M F. et al . A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.  J Clin Psychopharmacology. 2004;  24 365-373
    PubMedGoogle Scholar
  • 94 Ostroff R B, Nelson J C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.  J Clin Psychiatry. 1999;  60 256-259
    CrossrefPubMedGoogle Scholar
  • 95 Marangell L B, Johnson C R, Kertz B. et al . Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.  J Clin Psychiatry. 2002;  63 391-395
    PubMedGoogle Scholar
  • 96 Adson D E, Kushner M G, Eiben K M, Schulz S C. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors.  Depression and Anxiety. 2004;  19 121-126
    CrossrefPubMedGoogle Scholar
  • 97 Papakostas G I, Petersen T J, Nierenberg A A. et al . Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant depressive disorder.  J Clin Psychiatry. 2004;  65 217-221
    PubMedGoogle Scholar
  • 98 Shelton R C. The combination of olanzapine and fluoxetine in mood disorders.  Expert Opin Pharmacother. 2003;  4 1175-1183
    PubMedGoogle Scholar
  • 99 Shelton R C, Tollefson G D, Tohen M. et al . A novel augmentation strategy for treating resistant major depression.  Am J Psychiatry. 2001;  158 131-134
    CrossrefPubMedGoogle Scholar
  • 100 Doree J P, Tourjman V, Desrosiers J. et al .Comparison of quetiapine vs. lithium in treatment of resistant depression. New York, USA; 157th Annual Meeting of the APA May 1 - 6 2004
    Google Scholar
  • 101 Dunner L D, Amsterdam J D, Shelton R C. et al .Adjunctive ziprasidone in treatment-resistant depression: a pilot study. San Francisco, California; 156th Annual Meeting of the APA May 17 - 22 2003
    Google Scholar
  • 102 Oppenheim G. Estragen in the treatment of depression: neuropharmacological mechanisms.  Biol Psychiatry. 1983;  18 721-725
    PubMedGoogle Scholar
  • 103 Shapira B, Oppenheim G, Zoher J. et al . Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives.  Biol Psychiatry. 1985;  20 576-579
    CrossrefPubMedGoogle Scholar
  • 104 Sherwin B B. Estrogen and refractory depression. In: Amsteram JD Advances in Neuropsychiatry and Psychopharmacology, Vol 2: Refractory Depression. New York; Raven 1991: 209-218
    Google Scholar
  • 105 Flemenbaum A. Methylphenidate: A catalyst for the tricyclic antidepressants.  Am J Psychiatry. 1971;  128 239
    PubMedGoogle Scholar
  • 106 Chiarello R J, Cole J O. The use of psychostimulants in general psychiatry.  Arch Gen Psychiatry. 1987;  44 286-295
    PubMedGoogle Scholar
  • 107 Fawcett J, Kravietz H M, Zajecka M R. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.  J Clin Psychopharmacol. 1991;  11 127-132
    PubMedGoogle Scholar
  • 108 Stoll A L, Pillay S S, Diamond L. et al . Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series.  J Clin Psychiatry. 1996;  57 72-76
    PubMedGoogle Scholar
  • 109 Bader G, Hawley J M, Short D D. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report.  J Clin Psychopharmacol. 1998;  18 255-256
    CrossrefPubMedGoogle Scholar
  • 110 Linet L S. Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine (letter).  Am J Psychiat. 1989;  146 803-804
    PubMedGoogle Scholar
  • 111 Gupta S, Ghaly N, Dewan M. Augmenting fluoxetine with dextroamphetamine to treat refractory depression.  Hosp Com Psychiat. 1992;  43 281-283
    PubMedGoogle Scholar
  • 112 Warneke L. Psychostimulants in psychiatry.  Can J Psychiatry. 1990;  35 3-10
    PubMedGoogle Scholar
  • 113 McClellan K J, Spencer C M. Modafinil - a review of its pharmacology and clinical efficacy in the management of narcolepsy.  CNS Drugs. 1998;  9 311-324
    CrossrefPubMedGoogle Scholar
  • 114 Menza M A, Kaufman K R, Castellanos A. Modafinil augmentation of antidepressant treatment in depression.  J Clin Psychiatry. 2000;  61 378-381
    PubMedGoogle Scholar
  • 115 DeBattista C, Doghramji K, Menza M. et al . Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.  J Clin Psychiatry. 2003;  64 1057-1064
    PubMedGoogle Scholar
  • 116 Markovitz P, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.  J Clin Psychopharmacol. 2003;  23 1-3
    CrossrefPubMedGoogle Scholar
  • 117 Kaufman K R, Menza M A, Fitz-Simmons A. Modafinil monotherapy in depression.  Eur Psychiatry. 2002;  17 167-169
    PubMedGoogle Scholar
  • 118 Ninan P T, Hassman H A, Glass S J, McManus F C. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.  J Clin Psychiatry. 2004;  65 414-420
    PubMedGoogle Scholar
  • 119 Robertson jr P, Hellriegel E T. Clinical pharmacokinetic profile of modafinil.  Clin Pharmacokinet. 2003;  42 123-137
    CrossrefPubMedGoogle Scholar
  • 120 Pöldinger W. Combined administration of desipramine and reserpine or tetrabenazine in depressive patients.  Psychopharmacologia. 1967;  11 18-30
    PubMedGoogle Scholar
  • 121 Hopkinson G, Kenney F. Treatment with reserpine of patients resistant to tricyclic antidepressants.  Psychiatr Clin. 1975;  8 109-114
    PubMedGoogle Scholar
  • 122 Moscovich D, Mester R. Tricyclic antidepressive treatment reinforced by reserpine.  Isr J Psychiatr Rel Sci. 1984;  21 283-289
    PubMedGoogle Scholar
  • 123 Amsterdam J D, Berwish N. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy.  J Clin Psychopharmacology. 1987;  7 238-242
    PubMedGoogle Scholar
  • 124 Price L H, Charney D S, Heninger G R. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.  Psychopharmacology. 1987;  92 431-437
    PubMedGoogle Scholar
  • 125 Charney D S, Price L H, Heninger G R. Desipramine-Yohimbine combination treatment for refractory depression.  Arch Gen Psychiatry. 1986;  43 1155-1161
    PubMedGoogle Scholar
  • 126 Schmauß M, Laakmann G, Dieterle D. Effects of alpha-receptor blockade in addition to tricyclic antidepressants in therapy resistant depression.  J Clin Psychopharmacol. 1988;  8 108-111
    PubMedGoogle Scholar
  • 127 Rickels K, Amsterdam J D, Clary C. et al . Buspirone in major depression: a controlled study.  J Clin Psychiatry. 1991;  52 34-38
    PubMedGoogle Scholar
  • 128 Jacobsen F M. Possible augmentation of antidepressant response by buspirone.  J Clin Psychiatry. 1991;  52 217-230
    PubMedGoogle Scholar
  • 129 Bakish D. Fluoxetine potentiation by buspirone: three case histories.  Can J Psychiatry. 1991;  36 749-750
    PubMedGoogle Scholar
  • 130 Joffe R T, Schuller D R. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.  J Clin Psychiatry. 1993;  54 269-271
    PubMedGoogle Scholar
  • 131 Dimitriou E C, Dimitriou C E. Buspirone augmentation of antidepressant therapy.  J Clin Psychopharmacol. 1998;  18 465-469
    CrossrefPubMedGoogle Scholar
  • 132 Landen M, Bjorling G, Agren H. et al . A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment refractory depression.  J Clin Psychiatry. 1998;  59 664-668
    PubMedGoogle Scholar
  • 133 Kemp L I. Sodium valproate as an antidepressant.  Br J Psychiatry. 1992;  160 121-123
    PubMedGoogle Scholar
  • 134 Ballenger J C. The clinical use of carbamazepine in affective disorders.  J Clin Psychiatry. 1988;  49 (Suppl) 13-19
    PubMedGoogle Scholar
  • 135 Calabrese J R, Suppes T, Sachs G S. A double blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.  J Clin Psychiatry. 1999;  60 79-88
    CrossrefPubMedGoogle Scholar
  • 136 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 (Suppl 5) 51-58
    PubMedGoogle Scholar
  • 137 Boukoms A, Mangini L. Pergolide: an antidepressant adjuvant for mood disorders?.  Psychopharmacol Bull. 1993;  29 207-211
    PubMedGoogle Scholar
  • 138 Michelson D, Bancroft J, Targum S. et al . Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.  Am J Psychiatry. 2000;  157 239-243
    CrossrefPubMedGoogle Scholar
  • 139 Inoue T, Tsuchiya K, Miura J. et al . Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression.  Biol Psychiatry. 1996;  40 151-153
    CrossrefPubMedGoogle Scholar
  • 140 Sporn J, Ghaemi S N, Sambur M R. et al . Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review.  Ann Clin Psychiatry. 2000;  12 137-140
    CrossrefPubMedGoogle Scholar
  • 141 Lattanzi L, Cassano P, Dell'Osso L. et al .Adjunctive pramipexole in treatment resistant depression. Presented at the 39th Annual Meeting of the ACNP. San Juan, Puerto Rico; 2000; Dec 10 - 14
    Google Scholar
  • 142 Dawson L A, Nguyen H Q. The role of 5-HAT(1A) and 5-HAT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (±) pindolol.  Neuropharmacology. 2000;  39 1044-1052
    CrossrefPubMedGoogle Scholar
  • 143 Artigas F, Romero L, Montigny C de, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.  Trends Neurosci. 1996;  19 378-383
    CrossrefPubMedGoogle Scholar
  • 144 Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression.  J Clin Psychopharmacol. 1995;  15 217-222
    CrossrefPubMedGoogle Scholar
  • 145 Moreno F A, Gelenberg A J, Bachar K. et al . Pindolol augmentation of treatment-resistant depressed patients.  J Clin Psychiatry. 1997;  58 437-439
    PubMedGoogle Scholar
  • 146 Perez V, Soler J, Puigdemont D. et al . A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors.  Arch Gen Psychiatry. 1999;  56 375-379
    CrossrefPubMedGoogle Scholar
  • 147 Olver J S, Cryan J F, Burrows G D. et al . Pindolol augmentation of antidepressants: a review and rationale.  Aust N Z J Psychiatry. 2000;  34 71-79
    CrossrefPubMedGoogle Scholar
  • 148 Spillmann M, Fava M. S-adenosylmethionine (Ademetionine) in psychiatric disorders: historical perspective and current status.  CNS Drugs. 1996;  6 416-425
    PubMedGoogle Scholar
  • 149 Alpert J E, Pingol M G, Rankin M A. et al .Methylfolate as an adjunct in SSRI refractory depression. In: Syllabus and Proceedings Summary of the APA Meeting. Washington DC; May 15 - 20, 1999 No 75: 32
    Google Scholar
  • 150 Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.  J Affect Disord. 2000;  60 121-130
    CrossrefPubMedGoogle Scholar
  • 151 Warner M D, Peabody C A, Whiteford H A, Hollister L E. Alprazolam as an antidepressant.  J Clin Psychiatry. 1988;  49 148-150
    PubMedGoogle Scholar
  • 152 Petty F, Trivedi M H, Fulton M, Rush A J. Benzodiazepines as antidepressants: does GABA play a role in depression?.  Biol Psychiatry. 1995;  38 578-591
    CrossrefPubMedGoogle Scholar
  • 153 Bauer M, Whybrow P C, Angst J. WFSBP-Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder.  World J Biol Psychiatry. 2002;  3 5-43
    CrossrefPubMedGoogle Scholar

Prof. Dr. Max Schmauß

Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Bezirkskrankenhaus Augsburg

Dr.-Mack-Straße 1

86156 Augsburg

Email: m.schmauss@bkh-augsburg.de

      >